XML 64 R46.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Collaboration Agreements And Business Development Activities - Royalty Pharma (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended
--- | --- | ---
Oct. 31, 2022 | Dec. 29, 2023 | Dec. 30, 2022 | Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Collaboration agreement percent of royalty on net sale |  | 3.00% |  |
Collaborative Arrangements with Glaxo Smith Kline |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Collaboration agreement percent of royalty on net sale | 3.00% |  |  |
Collaborative Arrangements with Royalty Pharma |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Royalty expense |  | $ 68.0 | $ 58.2 | $ 46.6

X
- Definition Collaboration Agreement, Percent Of Royalty On Net Sale + References No definition available. + Details
Name: | exel_CollaborationAgreementPercentOfRoyaltyOnNetSale
Namespace Prefix: | exel_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementsWithRoyaltyPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |